Page 92«..1020..91929394..100110..»

Category Archives: Spinal Cord Injury Treatment

Pinning down the pain: Schwann cell protein plays major role in neuropathic pain

Posted: Published on March 27th, 2013

Mar. 27, 2013 An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, says a key protein in Schwann cells performs a critical, perhaps overarching, role in regulating the recovery of peripheral nerves after injury. The discovery has implications for improving the treatment of neuropathic pain, a complex and largely mysterious form of chronic pain that afflicts over 100 million Americans. The findings are published in the March 27, 2013 issue of the Journal of Neuroscience. Neuropathic pain occurs when peripheral nerve fibers (those outside of the brain and spinal cord) are damaged or dysfunctional, resulting in incorrect signals sent to the brain. Perceived pain sensations are frequently likened to ongoing burning, coldness or "pins and needles." The phenomenon also involves changes to nerve function at both the injury site and surrounding tissues. Not surprisingly, much of the effort to explain the causes and mechanisms of neuropathic pain has focused upon peripheral nerve cells themselves. The new study by principal investigator Wendy Campana, PhD, associate professor in UC San Diego's Department of Anesthesiology, with colleagues at UC San Diego and in Japan, Italy and New York, points to a surprisingly critical role … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Pinning down the pain: Schwann cell protein plays major role in neuropathic pain

Research and Markets Announces The Release of ‘Neuromodulation Market – Forecasts to 2017’

Posted: Published on March 26th, 2013

DUBLIN, March 25, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/t8zp6f/neuromodulation) has announced the addition of the "Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Research and Markets Announces The Release of ‘Neuromodulation Market – Forecasts to 2017’

Neuralstem Secures $8 Million In Debt Financing From Hercules

Posted: Published on March 26th, 2013

ROCKVILLE, Md., March 25, 2013 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced today that it secured $8 million in debt financing with Hercules Technology Growth Capital (HTGC), to fund the company's capital budget through late 2014. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) "This debt financing extends our cash runway well into late 2014 at a critical time in our clinical product development cycle. We have multiple NSI-566 cell therapy clinical trials planned this year, building on our successful ALS Phase I trial, including the upcoming phase II ALS in the U.S.; both chronic and acute spinal cord injury in the U.S. and South Korea, respectively; ALS in Mexico, and stroke in China, in addition to completing the NSI-189/Phase Ib trial in major depressive disorder," said Neuralstem's President and CEO Richard Garr. "We are pleased to have the support of leading life sciences and technology investor, Hercules." "Neuralstem's unique stem cell platform has the potential to address a serious unmet medical need in the ALS and spinal cord injury patient populations, as well as other indications. The team's progress to date is the result of years of meticulous research and development. We are proud to be a strong financial partner," said Chad Norman, managing director … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Neuralstem Secures $8 Million In Debt Financing From Hercules

Stem Cell Treatment for Spinal Cord Injury at the Stem Cell Institute in Panama – Daniel Campbell – Video

Posted: Published on March 14th, 2013

Stem Cell Treatment for Spinal Cord Injury at the Stem Cell Institute in Panama - Daniel Campbell After stem cell therapy at the Stem Cell Institute in Panama, Daniel Campbell describes how his condition has improved since his first treatment. Daniel is i... By: cellmedicine … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Stem Cell Treatment for Spinal Cord Injury at the Stem Cell Institute in Panama – Daniel Campbell – Video

InVivo Therapeutics Reports 2012 Financial Results, Provides Business Update

Posted: Published on March 14th, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported financial results for the year ended December 31, 2012 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic SCI. Today there is no effective treatment for the spinal cord for paralysis caused by SCIs, and the market potential is estimated to be over $10 billion. "The year 2012 has quickly become our most productive. We grew our research and development teams to support a pipeline that now exceeds seven new treatment options for neurotrauma, and weve established a GMP manufacturing facility capable of manufacturing our scaffold and hydrogels for human use, said Frank Reynolds, InVivo Chief Executive Officer. Were ready to start a first-in-man clinical trial of our biopolymer scaffolding in acute SCI patients, and we expect as many as five products to be either on the market or in clinical studies by the end of 2014. … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics Reports 2012 Financial Results, Provides Business Update

InVivo Therapeutics Sponsors 2013 RISE Above Paralysis Gala

Posted: Published on March 14th, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has renewed its support for the Greater Boston Chapter of the National Spinal Cord Injury Association (NSCIA), a non-profit organization that offers programs and services to those with spinal cord injury and disease. InVivo will serve as a Premier sponsor at the RISE Above Paralysis Gala this Saturday, March 16, 2013, an annual event hosted by the Greater Boston Chapter of the NSCIA. The evening will bring together individuals with SCI, family members, healthcare professionals, and benefactors for a silent auction, dinner and dancing. This years gala marks the 21st anniversary of the Greater Boston Chapter. Weve worked for years to be ready to begin human studies and as we await word from the FDA regarding our application were proud to once again be a part of the RISE Above Paralysis Gala, said Frank Reynolds, InVivo Chief Executive Officer. This is the fourth year that weve been a premier sponsor, and we look forward to another evening celebrating the lives of those living with SCI. Said David Estrada, Director of … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics Sponsors 2013 RISE Above Paralysis Gala

Spinal Cord Injury ¦ Treatment and Symptoms – Video

Posted: Published on March 12th, 2013

Spinal Cord Injury Treatment and Symptoms XXXXXX◅ Spinal Cord Injury treatment mdash; Finding the right information about Spinal Cord Injury treatment symptoms, is crucial to managing Spinal Cord Injur... By: MainMDcom … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Spinal Cord Injury ¦ Treatment and Symptoms – Video

Mind-controlled exoskeleton to help disabled people walk again

Posted: Published on March 9th, 2013

Mar. 7, 2013 Every year thousands of people in Europe are paralysed by a spinal cord injury. Many are young adults, facing the rest of their lives confined to a wheelchair. Although no medical cure currently exists, in the future they could be able to walk again thanks to a mind-controlled robotic exoskeleton being developed by EU-funded researchers. The system, based on innovative 'Brain-neural-computer interface' (BNCI) technology -- combined with a light-weight exoskeleton attached to users' legs and a virtual reality environment for training -- could also find applications in the rehabilitation of stroke victims and in assisting astronauts rebuild muscle mass after prolonged periods in space. In the United Kingdom, every eight hours someone suffers a spinal cord injury, often leading to partial or full lower-body paralysis. In the United States, more than 250 000 people are living with paralysis as a result of damage to their spinal cord, usually because of a traffic accident, fall or sporting injury. Many are under the age of 50, and with no known medical cure or way of repairing damaged spinal nerves they face the rest of their lives in a wheelchair. But by bypassing the spinal cord entirely and routing brain … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Mind-controlled exoskeleton to help disabled people walk again

Saneron and USF Patent Method for Umbilical Cord Blood Cell Use

Posted: Published on March 6th, 2013

Newswise TAMPA, Fla. - March 05, 2013 Researchers at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, (www.saneron-ccel.com) and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as Parkinsons disease, Huntingtons disease, multiple sclerosis, Alzheimers disease as well as brain and spinal cord injury. Human umbilical cord blood provides a rich source of hematopoietic (blood) multipotent stem cells that can differentiate and give rise to all of the blood cell types. A single cord blood sample provides enough hematopoietic stem cells to provide short and long-term engraftment with a low incidence of graft-versus-host disease, said Dr. Alison E. Willing, professor, Center of Excellence for Aging and Brain Repair, Department of Neurosurgery, University of South Florida and an inventor on the patent. The object of this newly patented process is a method for isolating and inducing pluripotent stem or progenitor cells into becoming neural or glial cells for use in stem cell transplantation procedures to treat neurodegenerative diseases as well as spinal cord … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Saneron and USF Patent Method for Umbilical Cord Blood Cell Use

Discovery of ‘executioner’ protein opens door to new options for stroke ALS, spinal cord injury

Posted: Published on March 6th, 2013

Mar. 4, 2013 Oxidative stress turns a protein that normally protects healthy cells into their executioner, according to a study released today in the Proceedings of the National Academy of Sciences journal. Alvaro Estevez, an associate professor at the University of Central Florida's College of Medicine, led the multi-university team that made the discovery, which could eventually help scientists develop new therapies to combat a host of conditions from stroke to Lou Gehrig's disease. Researchers have long known that oxidative stress damages cells and results in neurodegeneration, inflammation and aging. It was commonly believed that oxidation made a "crude," demolition-like attack on cells, causing them to crumble like a building in an earthquake, Estevez said. However, the latest findings show that oxidation results in a much more targeted attack to specific parts of the cell. Oxidative stress damages a specific "chaperone" cell protein called Hsp90. It plays a role in up to 200 different cell functions. But when a form of oxidative stress called tyrosine nitration modifies that protein, it turns into the cell "executioner" shutting it down. "The concept that a protein that is normally protective and indispensable for cell survival and growth can turn into a killing machine, … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Discovery of ‘executioner’ protein opens door to new options for stroke ALS, spinal cord injury

Page 92«..1020..91929394..100110..»